ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AFMD Affimed NV

5.30
-0.03 (-0.56%)
After Hours
Last Updated: 16:12:31
Delayed by 15 minutes

Period:

Draw Mode:

Volume 80,729
Bid Price 5.20
Ask Price 5.36
News (1)
Day High 5.4302

Low
2.235

52 Week Range

High
11.10

Day Low 5.11
Company Name Stock Ticker Symbol Market Type
Affimed NV AFMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.03 -0.56% 5.30 16:12:31
Open Price Low Price High Price Close Price Prev Close
5.33 5.11 5.4302 5.30 5.33
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
743 80,729 $ 5.33 $ 430,113 - 2.235 - 11.10
Last Trade Time Type Quantity Stock Price Currency
16:00:00 421 $ 5.30 USD

Affimed NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
79.15M 14.93M - 42.77M -86M -5.76 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Affimed NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AFMD Message Board. Create One! See More Posts on AFMD Message Board See More Message Board Posts

Historical AFMD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.295.654.775.1879,8350.010.19%
1 Month6.0777.204.2456.00516,015-0.777-12.79%
3 Months6.107.204.2456.00643,007-0.80-13.11%
6 Months4.7537.402.2354.90821,2610.54711.51%
1 Year7.49811.102.2355.87821,658-2.20-29.31%
3 Years77.60117.402.23542.791,392,164-72.30-93.17%
5 Years43.00117.402.23542.261,258,306-37.70-87.67%

Affimed NV Description

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Your Recent History

Delayed Upgrade Clock